Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public

Added by pmartino
Group name EquipePM
Item Type Journal Article
Title [Strategies of tumor-pecific targeting based on the antigenic tumor specificities and the tumor microenvironment characteristics]
Creator Mangeat et al.
Author Tristan Mangeat
Author Matthieu Gracia
Author Pierre Martineau
Author Bruno Robert
Abstract Monoclonal antibody (mAb)-based immunotherapy is booming in oncology. In 2020, more than 40% of FDA (Food and Drug Administration)-approved antibodies (34 out of 84 antibodies, according to The Antibody Society) have an indication for cancer therapy. In contrast to standard chemotherapy, they demonstrate a much better safety profile for patients. Despite this, adverse side effects may occur due to the targeting of the antigen also expressed by healthy tissues. For this reason, emerging strategies aim at optimizing the antibody format and considering the particularities of the tumor microenvironment to confer a more specific action of the antibody at the tumor site.
Publication Medecine Sciences: M/S
Volume 36 Hors série n° 1
Pages 56-60
Date 2020-10
Journal Abbr Med Sci (Paris)
Language fre
DOI 10.1051/medsci/2020194
ISSN 1958-5381
Library Catalog PubMed
Extra 00000 PMID: 33052096
Tags Animals, Antibodies, Monoclonal, Antibody Specificity, Antigens, Neoplasm, corresponding, Drug Delivery Systems, Epitope Mapping, first, first-last-corresponding, Humans, last, Molecular Targeted Therapy, Neoplasms, Prodrugs, review, Revue, top, Tumor Hypoxia, Tumor Microenvironment
Date Added 2021/03/05 - 09:48:41
Date Modified 2021/09/01 - 09:36:55
Notes and Attachments Full Text (Attachment)
Full Text (Attachment)
Full Text (Attachment)
Full Text (Attachment)
PubMed entry (Attachment)
PubMed entry (Attachment)
PubMed entry (Attachment)
PubMed entry (Attachment)


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés